Mpox was first identified in the Democratic Republic of the Congo (DRC) in 1970. In 2023, a historic outbreak of mpox occurred in the country, continuing into 2024. Over 14 000 cases and 600 deaths were reported in 2023 alone, representing a major increase from previous outbreaks. The modified vaccinia Ankara vaccine (brand names JYNNEOS, Imvamune, and Imvanex) was used in the 2022 mpox outbreak in the USA and Europe. However, at the time of the study, vaccination had not been made available in the DRC. We aimed to inform policy and decision makers on the potential benefits of, and resources needed, for mpox vaccination campaigns in the DRC by providing counterfactual scenarios evaluating the short-term effects of various vaccination strategies on mpox cases and deaths, if such a vaccination campaign had been undertaken before the 2023–24 outbreak.

中文翻译：

---

刚果民主共和国遏制和缓解 mpox 的疫苗接种方法建模


猴痘于 1970 年在刚果民主共和国 （DRC） 首次被发现。2023 年，该国发生了历史性的猴痘疫情，并持续到 2024 年。仅在 2023 年，就报告了超过 14000 例病例和 600 例死亡，比以前的疫情大幅增加。改良的安卡拉牛痘疫苗（商品名 JYNNEOS、Imvamune 和 Imvanex）用于 2022 年美国和欧洲的猴痘疫情。然而，在研究进行时，DRC 尚未提供疫苗接种。我们旨在通过提供反事实情景来评估各种疫苗接种策略对 mpox 病例和死亡的短期影响，如果此类疫苗接种活动在 2023-24 年爆发之前进行，我们旨在让政策和决策者了解刚果民主共和国 mpox 疫苗接种活动的潜在益处和所需的资源。